{"title":"Different approach to M descriptor for future staging of oligometastatic disease in SCLC: A cross-sectional survival analysis.","authors":"Melahat Uzel Şener, Pınar Akın Kabalak, Suna Kavurgacı, Nilgün Yılmaz Demirci, Derya Kızılgöz, Fazlı Yanık, Sinem Ermin, Yasemin Söyler, Yekta Altemur Karamustafaoğlu, Demet Türkay Pakna, Ahmet Dumanlı, Ülkü Yılmaz","doi":"10.1007/s12094-024-03778-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC).</p><p><strong>Methods: </strong>This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2-5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted.</p><p><strong>Results: </strong>The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9-12.5), 7.5 months (95% CI 5.6-9.4), 4.3 months (95% CI 2.9-5.7), and 5.4 months (95% CI 4.7-6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2-15.3), 9.5 months (95% CI 7.1-11.9), 7.1 months (95% CI 4.5-9.7), and 6.9 months (95% CI 6.0-7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups.</p><p><strong>Conclusion: </strong>There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03778-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC).
Methods: This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2-5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted.
Results: The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9-12.5), 7.5 months (95% CI 5.6-9.4), 4.3 months (95% CI 2.9-5.7), and 5.4 months (95% CI 4.7-6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2-15.3), 9.5 months (95% CI 7.1-11.9), 7.1 months (95% CI 4.5-9.7), and 6.9 months (95% CI 6.0-7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups.
Conclusion: There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.
目的：本研究旨在探讨寡转移和M描述因子对小细胞肺癌（SCLC）生存期的影响：这项多中心回顾性研究纳入了2010年至2020年新诊断的广泛期SCLC（ES-SCLC）患者。分组：第1组：单个器官有转移；第2组：单个器官有2-5个转移；第3组：单个器官有6个或更多转移；第4组：两个或更多器官有转移。这一分类是根据第 9 次分期-M 描述法进行的。进行了三年无进展生存期（PFS）和总生存期（OS）分析：439名患者的平均年龄为（62±10）岁，89.5%为男性。第1、2、3、4组的平均生存期分别为10.7个月（95% CI 8.9-12.5）、7.5个月（95% CI 5.6-9.4）、4.3个月（95% CI 2.9-5.7）和5.4个月（95% CI 4.7-6.1）。第 2 组的 PFS 明显更高。第1、2、3、4组的平均OS分别为13.3个月（95% CI 11.2-15.3）、9.5个月（95% CI 7.1-11.9）、7.1个月（95% CI 4.5-9.7）和6.9个月（95% CI 6.0-7.9）。第一组的 OS 明显更高。M1b组的OS和PFS明显高于M1c1组和M1c2组（P 结论：M1b组的OS和PFS明显高于M1c1组和M1c2组：M1c1组和M1c2组的生存率无明显差异。在 ES-SCLC 中，转移灶的数量可能比转移器官的数量更能预测预后。
期刊介绍：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
